MTOR and hepatocellular carcinoma: In our current study, we have uncovered that Ezetimibe has the ability to induce paraptosis in hepatocellular carcinoma (HCC) cells through mechanisms involving endoplasmic reticulum (ER) stress, the unfolded protein response (UPR), and activation of the PI3K/AKT/mTOR and MAPK/JNK signaling pathways.